B-MS in three-way alliance to 'map out lung cancer immunology'

Bristol-Myers Squibb (NYSE: BMY) has entered a collaboration with two UK partners that comes with the promise of creating a ‘rule book’ to guide precision combination immunotherapies and to speed up the development of new lung cancer treatments.

The US pharma major is contributing £2.4 million ($3.1 million) to the research project called RUBICON, which also involves the charity Cancer Research UK (CRUK) and the Francis Crick Institute.

Charles Swanton, chief clinician at CRUK and group leader at Francis Crick, said: “Biological therapies, including immunotherapies are set to transform the way we treat patients and the RUBICON study will bring us a step closer to this vision.